“…The treatment of GVHD has hinged on 2 schools of thought, those being increasing or decreasing of immunosuppression and immunomodulation. Reported treatment modalities have included corticosteroids, withdrawal of immunosuppression, use of anti‐thymocyte globulin or alemtuzumab (Campath), other immunomodulatory drugs such as etanercept, and extracorporeal photopheresis . A recent review of literature involved 34 patients (not involving LT recipients) with CNS‐GVHD who were treated with immunosuppressive therapy, including corticosteroids, intravenous immunoglobulin, plasmapheresis, cyclophosphamide, calcineurin inhibitors, mycophenolic acid, methotrexate, and etoposide, with 10 achieving complete and 15 more achieving partial responses .…”